GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
2.6400
-0.1000 (-3.65%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.7400
Open2.7400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.5250 - 2.7400
52 Week Range0.0857 - 3.2800
Volume39,446
Avg. Volume117,059
Market Cap159.356M
Beta (3Y Monthly)-2.65
PE Ratio (TTM)11.58
EPS (TTM)0.2280
Earnings DateSep 19, 2019 - Sep 23, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast Cancer

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the NSABP Foundation, Inc. (NSABP) has enrolled the first patient in the study: A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer (NSABP FB-14). The trial, conducted in conjunction with research partners Merck and the NSABP Foundation, is designed to evaluate the safety and tolerability of AE37 given in combination with KEYTRUDAÒ (pembrolizumab) as well as the objective response rate. Eric von Hofe, President of NuGenerex-ImmunoOncology commented, “This is an exciting milestone for NuGenerex Immuno-Oncology, as we have now revitalized our AE37 development program with a focus on combination therapy with checkpoint inhibitors, which are now becoming standard of care for a broad array of cancers.

  • GlobeNewswire

    Generex Announces That the Process to Retire 20,375,900 GNBT “Pool Shares” is Complete

    Retirement of Pool shares will be Reflected in 31.9% reduction in Outstanding Shares MIRAMAR, Fla., Sept. 16, 2019 -- Generex Biotechnology Corporation (www.generex.com).

  • GlobeNewswire

    Generex Biotechnology Announces Webcast and Invites All Shareholders to See and Listen to the Corporate Presentation from the 21st Annual H.C. Wainwright Global Healthcare Investment Conference

    Generex Biotechnology Corporation (GNBT) is pleased to announce that the presentation delivered by Joe Moscato, President & Chief Executive Officer and Richard Purcell, Senior Vice President of Research to the H.C. Wainwright Global Healthcare Investment Conference on Monday September 9, 2019 is now available as a webcast. Mr. Moscato and Mr. Purcell presented the Generex corporate strategy and operating plan, ongoing plans for up-listing GNBT to Nasdaq, and the exciting news about the pending acquisition of ALTuCELL and partnerships with Arizona Endocrinology Center and Paradise Valley Family Medicine to advance the treatment and management of diabetes through the NuGenerex end-to-end model for integrated disease management.

  • GlobeNewswire

    Generex Biotechnology Signs Letters of Intent to Establish NuGenerex Health MSO with Arizona Endocrinology Center & Paradise Valley Family Medicine

    Generex Biotechnology Corporation (GNBT) announces that the Company has signed letters of intent with Arizona Endocrinology Center and Paradise Valley Family Medicine to establish NuGenerex Health, LLC, a management services organization (MSO) focused on the delivery and management of healthcare services for patients with chronic, complex medical conditions, particularly diabetes. Together, the two medical practices currently work in concert to provide primary care and specialty endocrinology healthcare services for a patient population of roughly 65,000 patients, 25,000 of whom are insulin-dependent diabetes patients.

  • GlobeNewswire

    Generex Biotechnology Signs Letter of Intent to Acquire 51% in ALTuCELL, Inc. and their Cellular Therapy Product Altsulin® with Patented Microencapsulation Technology for the Treatment of Type I Diabetes Mellitis

    Patented cell encapsulation technology enables cell implantation for therapeutic and regenerative medicine application without immune system rejectionMicrocapsules formulated.

  • GlobeNewswire

    Generex Announces Date for Annual Shareholder Meeting and Pending Retirement of 20,375,900 GNBT “Pool Shares”

    Shareholders of record as of September 3, 2019 are eligible to vote at the shareholders meeting. In the next two weeks, shareholders will receive proxy materials from the Company’s transfer agent Broadridge together with voting instructions.  Details of the time and location for the meeting will be announced in the near future. Also today, Generex is pleased to announce that Joe Moscato, President and Chief Executive Officer today began the legal and regulatory process to retire the 20,375,900 “Pool” shares he controls for the benefit of Generex.

  • GlobeNewswire

    Generex Announces Webcast

    “We are excited for next week’s H.C. Wainwright conference where we will be announcing details on a number of exciting business deals for the NuGenerex family of companies and a major acquisition in the diabetes space,” stated Joe Moscato, CEO of Generex. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies.

  • GlobeNewswire

    Generex Biotechnology Confirms Record Date for 1:1 Dividend

    Generex Biotechnology Corporation (GNBT) today confirmed that the record date for the 1:1 (100%) stock dividend was recorded on August 30, 2019, and the dividend will be paid on October 29th  to all shareholders who hold their shares through the ex-date of October 30, 2019. Anyone who sells their shares before the market close on October 30th will lose the dividend, which will be transferred to the buyer of your shares, just as anyone buying shares from now through October 30th will receive the 1:1 (100%) dividend from the seller of the shares. Management and company insiders, note holders, acquisition partners, and the pool shares controlled by Generex President & CEO Joe Moscato on behalf of the Pool owners have waived their rights to the dividend.

  • GlobeNewswire

    Generex Biotechnology Announces Time Slot for CEO Joe Moscato to Present at H.C. Wainwright Healthcare Conference

    H.C. WAINWRIGHT 21st ANNUAL GLOBAL INVESTMENT CONFERENCEThe Lotte New York Palace Hotel, New York, NY September 8 – 10, 2019 Mon, Sep 9 at 3:25-3:50 PM in Holmes II (4th.

  • GlobeNewswire

    Generex Biotechnology Reiterates 1:1 Stock Dividend for Clarity in the Market and Provides Details on Capital Structure

    Generex Biotechnology Corporation (www.generex.com) (GNBT) today provided additional guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders. Due to high call volume and ongoing confusion in the market related to the upcoming 1:1 stock dividend, we would like to reiterate the terms of the dividend to be paid to shareholders.

  • GlobeNewswire

    Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (“Generex”) is pleased to announce that Generex has acquired an additional 38% of Olaregen Therapeutix for a total Generex ownership of approximately 99% after the share exchange at $2.50 a share for GNBT stock, in a cashless transaction. Also, Generex is pleased that today it paid the final payment of $138,000 to a noteholder to satisfy an outstanding note, which together with the payment of $900,000 on Friday August 16, clears over $1 million in debt from the books to further strengthen the Generex balance sheet as the Nasdaq up-list application is being processed. Joseph Moscato, Generex President & Chief Executive Officer stated, “We are thrilled to acquire an additional 38% of Olaregen as we launch ExcellagenÒ into the marketplace.

  • GlobeNewswire

    Generex Biotechnology Announces Plans for NuGenerex Immuno-Oncology Spinout through a Targeted Acquisition of a Public Company and Planned Merger with Kiromic

    Generex Biotechnology (www.generex.com) (GNBT) today announced that the Company has identified a public, development stage company that is fully reporting and current on its filings with the SEC, and DTC eligible that will serve as a vehicle for the spin-out of its subsidiary NuGenerex Immuno-Oncology (NGIO) as a separate public company. Generex is in final negotiations to retain the controlling interest of the outstanding shares of the acquisition target and expects to complete the contracts and file a super 8K in the coming weeks. Generex and its shareholders who have received the 1:4 NGIO dividend will initially hold 100% of the NGIO shares following the acquisition, which will set the stage for the subsequent planned merger with Kiromic.

  • GlobeNewswire

    Generex Biotechnology Defines 1:1 Stock Dividend and Provides Details on Capital Structure

    Generex Biotechnology Corporation (www.generex.com) (GNBT) today provided additional guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders. Due to high call volume and ongoing confusion in the market related to the upcoming 1:1 stock dividend, we would like to reiterate the terms of the dividend to be paid to shareholders.

  • GlobeNewswire

    Generex Biotechnology Announces Update to the Previously Declared 1:1 Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (“Generex”) today announced that it was proceeding with the dividend in anticipation of listing on Nasdaq. The Company remains optimistic in its ability to list on Nasdaq and with the confusion by the shareholders on the pay date, Generex wanted to provide its shareholders with a definitive Pay Date.

  • GlobeNewswire

    Generex News Alert: Generex to Announce Positive Shareholder News on Monday August 12, 2019 at 8 AM Payment Details for the 1:1 GNBT Stock Dividend

    MIRAMAR, Fla., Aug. 09, 2019 -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today provided a news alert for GNBT shareholders that the Company.

  • GlobeNewswire

    Generex Biotechnology Announces Interview with President & CEO Joe Moscato

    During the interview, Mr. Moscato spoke about the recent acquisitions of MediSource Partners and Pantheon Medical, the launch of Excellagen by Generex’ subsidiary Olaregen, and the Generex corporate strategy of building specialty networks to provide end-to-end, patient centric solutions that enhance the doctor/patient relationship. Mr. Moscato also spoke about the planned Nasdaq up-list and the associated 1:1 dividend. “My entire focus is on building value for our shareholders through execution on our strategy at Generex.

  • GlobeNewswire

    Generex Biotechnology Welcomes MediSource Partners to the NuGenerex Family of Companies

    Generex Biotechnology Corporation (www.generex.com) (GNBT) is pleased to welcome MediSource Partners (https://medisourcepartners.com) to the NuGenerex family of subsidiary companies. MediSource is a national distributor of medical devices, orthopedic implants, surgical kits, and biologics and cellular tissue products (C/TPs). Additionally, MediSource has built a national network of partner organizations through which to broker mutually beneficial deals between healthcare providers and partners in the network to structure and implement value added agreements that reduce costs and increase efficiency.

  • GlobeNewswire

    Generex Biotechnology Introduces Pantheon Medical, the Newest Member of the NuGenerex Family of Companies

    Generex Biotechnology Corporation (www.generex.com) (GNBT) is proud to introduce Pantheon Medical (https://pantheonortho.com) as the newest member of the NuGenerex family of subsidiary companies. Pantheon is a manufacturer of orthopedic foot & ankle surgery kits that offer physician friendly “all-in-one,” integrated surgical kits that include plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. The number of orthopedic surgeries, including hip & knee replacements, ankle & foot repairs and corrections, and fracture repairs continue to climb due to the aging population and the increased prevalence of obesity, which can lead to joint problems, particularly in the lower extremities.

  • GlobeNewswire

    Generex Biotechnology Provides Guidance on 1:1 Stock Dividend

    Joseph Moscato, Generex President & Chief Executive Officer stated, “Many thanks to our shareholders and interested parties for participating in our conference call last Thursday, July 25. Since then, I have received a number of calls pertaining to the 1:1 shareholder dividend, so I want to provide some clarity with this release.

  • GlobeNewswire

    Generex Biotechnology Provides a Summary of Its Investor Conference Call Held on July 25, 2019

    Generex Biotechnology Corporation (www.generex.com) (GNBT) today provided a summary of the investor conference call held yesterday, July 25, 2019 at 4:00 pm during which Joseph Moscato, Generex President & Chief Executive Officer updated investors on the company’s plans for the GNBT up-list and the previously declared 1:1 share dividend.  He also provided guidance on the proposed timing for the NuGenerex Immuno-Oncology (NGIO) spinout and subsequent planned merger with Kiromic. Mr. Moscato stated: “Many thanks to our shareholders and interested parties for calling in yesterday to hear about our progress in achieving stage 3 of our plan to bring Generex back to the Nasdaq.

  • GlobeNewswire

    Reminder: Investor Conference Call Today July 25, 2019 Management to Provide Details on Generex Up-list and 1:1 Stock Dividend

    MIRAMAR, Fla., July 25, 2019 -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following.

  • GlobeNewswire

    Generex Biotechnology Announces Satisfaction of Debt Obligation

    Retires $3,150,972 in debt and satisfies all associated obligationsPayment in GNBT restricted common shares at the July 16, 2019 closing price MIRAMAR, Fla., July 19, 2019 --.

  • GlobeNewswire

    Generex Biotechnology Announces Investor Conference Call Scheduled for July 25, 2019

    MIRAMAR, Fla., July 16, 2019 -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Thursday July.

  • GlobeNewswire

    Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors APMA Annual Scientific Meeting

    Olaregen Silver SponsorshipDr. Lois Chandler, PhD Presents Excellagen Research as Keynote Speaker at Wound Care SymposiumRapid Acceleration of Healing with Wound Conforming,.

  • GlobeNewswire

    Generex Biotechnology Announces Closing on Acquisition of MediSource Partners

    Generex Biotechnology Corporation (GNBT) is pleased to announce the Company has completed the acquisition agreement to acquire assets and operations of Medisource Partners, an FDA-registered distributor of medical and surgical products including bone grafts and biologics from a range of surgical product manufacturers. Under the terms of the deal, Generex will acquire 100% of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, in an all-stock transaction, effective August 1, 2019, following the close of Generex’ fiscal year.